CT26 cells were established by engineering the Balb/c syngeneic tumor line CT26 to express human Her2 (39) as a naturally resistant model for anti-p185erbB2 antibody therapies as it carries the oncogenic K-RasG12D mutation (40, 41). This evidence concerns the gene ERBB2 and neoplasm.